切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 166 -169. doi: 10.3877/cma.j.issn.1674-0785.2020.03.003

所属专题: 文献 指南共识

指南解读

美国胃肠病协会临床实践指南解读:胃黏膜肠上皮化生的管理(2019年)
玉珍1, 戴芸2,()   
  1. 1. 850000 拉萨,西藏自治区人民医院消化内科
    2. 100034 北京大学第一医院消化内科
  • 收稿日期:2020-02-14 出版日期:2020-03-15
  • 通信作者: 戴芸

Interpretation of American Gastroenterological Association clinical practice guidelines on management of gastric intestinal metaplasia (2019 edition)

Zhen Yu1, Yun Dai2,()   

  1. 1. Department of Gastroenterology, Tibet Autonomous Region People′s Hospital, Lhasa 850000, China
    2. Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China
  • Received:2020-02-14 Published:2020-03-15
  • Corresponding author: Yun Dai
  • About author:
    Corresponding author: Dai Yun, Email:
引用本文:

玉珍, 戴芸. 美国胃肠病协会临床实践指南解读:胃黏膜肠上皮化生的管理(2019年)[J]. 中华临床医师杂志(电子版), 2020, 14(03): 166-169.

Zhen Yu, Yun Dai. Interpretation of American Gastroenterological Association clinical practice guidelines on management of gastric intestinal metaplasia (2019 edition)[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(03): 166-169.

胃癌在全球癌症相关性死亡率中排名第3位。胃黏膜肠上皮化生(GIM)为一种常见的癌前病变,与胃癌发生密切相关。根据循证医学的证据,2019年12月美国胃肠病协会(AGA)发布了针对GIM患者管理的临床实践指南。本文将就该指南中的主要推荐意见进行解读。

Gastric cancer is the third leading cause of cancer death worldwide. Gastric intestinal metaplasia (GIM) represents the histologic step prior to the development of dysplasia and is routinely encountered in clinical practice, which has been associated with an increased risk for gastric cancer. Recently, the American Gastroenterological Association published evidence-based guidelines for management of patients with GIM incidentally detected on gastric biopsies. Herein, we mainly explain some controversial issues in such guidelines.

1
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2
Gupta S, Tao L, Murphy JD, et al. Race/Ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer [J]. Gastroenterology, 2019, 156(1): 59-62.
3
Correa P. Gastric cancer: overview [J]. Gastroenterol Clin North Am, 2013, 42(2): 211-217.
4
Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening [J]. Jpn J Clin Oncol, 2008, 38(4): 259-267.
5
Zhang X, Li M, Chen S, et al. Endoscopic screening in asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review [J]. Gastroenterology, 2018, 155(2): 347-354.
6
Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia [J]. Gastroenterology, 2019 Dec 6. pii: S0016-5085(19)41888-X.
7
Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori [J]. Int J Cancer, 2014, 136(2): 487-490.
8
Evans JA, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the anagement of premalignant and malignant conditions of the stomach [J]. Gastrointest Endosc, 2015, 82(1): 1-8.
9
Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 [J]. Endoscopy, 2019, 51(4): 365-388.
10
Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication [J]. Gut, 2004, 53(9): 1244-1249.
11
Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years [J]. Aliment Pharmacol Ther, 2018, 47(3): 380-390.
12
Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial [J]. JAMA, 2004, 291(2): 187-194.
13
Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection [J]. Aliment Pharmacol Ther, 2005, 22(5): 471-481.
14
Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system [J]. Gut, 2007, 56(5): 631-636.
15
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis [J]. Gastrointest Endosc, 2010, 71(7): 1150-1158.
16
Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions [J]. Endoscopy, 2012, 44(3): 236-246.
17
Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial [J]. Gastrointest Endosc, 2017, 86(5): 857-865.
[1] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[2] 张瑜, 李冉, 彭书芳, 刘玲. 胃癌术后发生腹腔间隔室综合征并发呼吸衰竭患者救治成功一例[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 453-454.
[3] 王甜甜, 温媛, 李振, 叶美红, 郭影, 马双. 和厚朴酚调控Nrf2/ARE通路对胃癌细胞的顺铂化疗敏感性的影响[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 202-209.
[4] 刘先勇. 胃Lgr5+干细胞、Mist1+干细胞和Cck2r+干细胞癌变的分子机制[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 183-188.
[5] 张馨月, 韩帅, 张舒石, 李文臣, 张舒岩. 颅内压监测技术在创伤性颅脑损伤治疗中的应用[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 246-252.
[6] 李强, 臧迪, 任鸿翔. 耳蜗电图与脑干听觉诱发电位的联合监测在桥小脑角胆脂瘤切除术中的应用[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 253-256.
[7] 韩晓娟, 徐佳倩, 朱玉兰, 王莹, 李源, 冯珺, 邵东. HHLA2过表达胃癌细胞株构建及细胞功能的初步研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 373-377.
[8] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[9] 孙秀艳, 徐庆蕾, 马鹏涛, 胡志元, 郭传真, 祝成红. 腹腔镜胃癌根治术中患者体温变化与压力性损伤及受压部位微环境的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 480-484.
[10] 杨镠, 秦岚群, 耿茜, 李栋庆, 戚春建, 蒋华. 可溶性免疫检查点对胃癌患者免疫治疗疗效和预后的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 305-311.
[11] 徐洪宇, 何亚爽. 羟考酮与氢吗啡酮用于胃癌根治术后镇痛的疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 312-316.
[12] 盛静, 梅勇, 夏佩, 王晓林. 乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 317-321.
[13] 董青, 丁飞, 郭浩, 李峰. Nesfatin-1/NUCB2在幽门螺杆菌感染相关早期胃癌患者中的表达及临床意义[J]. 中华临床医师杂志(电子版), 2023, 17(07): 783-789.
[14] 邱学荣, 张秀琴, 张欢, 刘婷, 高翠琴. 动态监测SAA给予抗生素在电子支气管镜联合普米克令舒治疗重症肺炎中的价值研究[J]. 中华临床医师杂志(电子版), 2023, 17(03): 308-313.
[15] 王佳凤, 郭锐, 陈倩倩, 李惠凯, 宁波, 袁新普, 朱华, 令狐恩强. 68Ga-NC-BCH联合PET-CT淋巴结免疫示踪对于胃癌患者术前及术后临床决策影响的初步探索研究[J]. 中华胃肠内镜电子杂志, 2023, 10(04): 253-257.
阅读次数
全文


摘要